SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Company Response from Elicio Therapeutics, (ELTX) — Dec 1, 2025

Elicio Therapeutics, Inc.
Date: Dec. 1, 2025 · CIK: 0001601485 · Accession: 0001601485-25-000128

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-291515

Date
December 1, 2025
Author
Robert Connelly
Form
CORRESP
Company
Elicio Therapeutics, Inc.

Letter

Document ELICIO THERAPEUTICS, INC. 451 D Street, 5 th Floor Boston, MA 02210 December 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed November 13, 2025 File No. 333-291515 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Wednesday, December 3, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request. Very truly yours, ELICIO THERAPEUTICS, INC. /s/ Robert Connelly Robert Connelly Chief Executive Officer cc: Elicio Therapeutics, Inc. Megan Filoon

Show Raw Text
CORRESP
 1
 filename1.htm

 Document ELICIO THERAPEUTICS, INC. 451 D Street, 5 th Floor Boston, MA 02210 December 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed November 13, 2025 File No. 333-291515 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Wednesday, December 3, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request. Very truly yours, ELICIO THERAPEUTICS, INC. /s/ Robert Connelly Robert Connelly Chief Executive Officer cc: Elicio Therapeutics, Inc. Megan Filoon